[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352654-105":59,"doc-detail-352654-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","low-e-cadherin-expression-is-associated-with-poor-prognosis-in-pulmonal-adenocarcinoma","Low E-cadherin expression is associated with poor prognosis in pulmonal adenocarcinoma","","Low E-cadherin is an adhesion molecule with tumor-suppressive function, and reduced membranous expression is investigated as a driver of progression and metastasis in lung cancer. Using immunohistochemistry on a tissue microarray of 857 resected lung cancers, membranous staining was present in 779 of 804 evaluable tumors. Loss occurred infrequently in NSCLC but was more common in adenocarcinomas than squamous cell carcinomas, with reduced expression linked to advanced stage, higher grade, and worse survival in adenocarcinomas.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/low-e-cadherin-expression-is-associated-with-poor-prognosis-in-pulmonal-adenocarcinoma/352654/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/low-e-cadherin-expression-is-associated-with-poor-prognosis-in-pulmonal-adenocarcinoma/352654.png","ImageObject",300,407,{"name":92,"@type":93},"WPS_1786070896","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main purpose of measuring E-cadherin in lung cancer samples?","Question",{"text":112,"@type":113},"To determine how common reduced E-cadherin expression is across lung cancer subtypes and whether it relates to disease progression, clinicopathological features, and patient survival.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was E-cadherin expression assessed in this study?",{"text":117,"@type":113},"E-cadherin expression was analyzed by immunohistochemistry (IHC) on a tissue microarray (TMA) containing 857 lung cancer tissue samples.",{"name":119,"@type":110,"acceptedAnswer":120},"In which lung cancer subtype was E-cadherin loss more frequent?",{"text":121,"@type":113},"Loss of E-cadherin expression was reported as slightly more frequent in adenocarcinomas than in squamous cell carcinomas.",{"name":123,"@type":110,"acceptedAnswer":124},"What does reduced E-cadherin expression indicate about prognosis?",{"text":125,"@type":113},"Reduced E-cadherin expression was significantly associated with advanced pT stage and high grade in adenocarcinomas, and univariate outcome analysis linked it to poorer survival in NSCLCs and adenocarcinomas.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},352654,1790514727,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nLow E-cadherin expression is associated with poor prognosis in pulmonal adenocarcinoma  \nFiete Gehrisch1,2, Kiara A. Schmid1, Martina Kluth1,  \nGeorgia Makrypidi-Fraune1, Katharina Möller1, Maximilian Lennartz1, Veit Bertram1, Florian Lutz1, Stefan Steurer1, Philipp Busch2, Birgit Hantzsch-Kuhn3, Martin Reck3, Till Olchers3, David Benjamin Ellebrecht4, Christoph Fraune1,5, Ronald Simon1􀀍, Guido Sauter1 & Sönke von Weihe4  \nE-cadherin is a critical cell adhesion molecule with a tumor suppressive role. Reduced membranous E-cadherin expression is considered a central step in the progression and metastatic spread in human cancers. To study the prevalence and potential role of reduced E-cadherin expression in different lung cancer subtypes, E-cadherin expression was analyzed in more than 850 resected lung cancers by IHC in a tissue microarray format. A membranous E-cadherin staining was seen in 779 (96.9%) of the 804 interpretable tumor samples. A loss of E-cadherin expression was slightly more frequent inadenocarcinomas (ACs; 1.1%) than in squamous cell carcinomas (SCCs; 0.0%; p \u003C 0.0001). Among the less common tumor entities, E-cadherin immunostaining was absent in 57.1% of 35 mesotheliomas, but retained in all cases of carcinoid (n = 52), large cell neuroendocrine carcinoma (n = 19), undifferentiated large cell carcinoma (n = 3), carcinosarcoma (n = 2), pleiomorphic carcinoma (n = 11), adenosquamous carcinoma (n = 8), mucoepidermoid carcinoma (n = 1), lymphoepithelial carcinoma (n = 1), and SMARCA4-deficient undifferentiated tumors (n = 1). Reduced E-cadherin immunostaining was significantly linked to advanced pT stage (p = 0.0265) and high grade (p = 0.0351) inACs. Univariate outcome analysis revealed a significant association between E-cadherin expression and patient survival in all NSCLCs (p \u003C 0.0001) and inACs (p = 0.0133) . It is concluded that loss of E-cadherin expression occurs in only a small subset of NSCLCs, that it is more frequent inACs compared to SCCs and that reduced E-cadherin expression is linked to poor prognosis and unfavorable histopathological features inACs. Should targeted therapy become available in the future, a small subset of pulmonary ACs and many mesotheliomas could be candidates for treatment.  \nAbbreviations  \nNSCLC Non-small lung carcinoma  \nAC Adenocarcinoma  \nSCC Squamous cell carcinoma  \nEMT Epithelial to mesenchymal transition IHC Immunohistochemistry  \nTMA Tissue microarray  \nIWGAV International Working Group of Antibody Validation  \nLung cancer is the leading cause for cancer-related deaths worldwide, accounting for an estimated 125,000 deaths annually in the U.S. alone1. During their lifetime 1 in 17 women and 1 in 16 men in the U.S. will be diagnosed with this disease1. Lung cancer has traditionally been classified into two histological subtypes: small-cell lung cancer and non-small-cell lung cancer (NSCLC), with NSCLC making up for 85% of all cases2. Among NSCLC, adenocarcinoma (AC) (50%) and squamous cell carcinoma (SCC) (20–30%) are the most prevalent subtypes3,4. Despite therapeutic advances, the 5-year survival rate remains at approximately 20%1, reflecting that NSCLC  \n1Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.  \n2Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungenClinic, Grosshansdorf, Germany. 4Department of Thoracic Surgery, Airway Research Center North, German Center for Lung Research, LungenClinic, Grosshansdorf, Germany. 5Institute of Pathology, Clinical Center Osnabrueck, Osnabrueck, Germany. 􀀍 email: [r.simon@uke.de](r.simon@uke.de)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nremains an incurable disease for the majority of patients","cbCairAM1G1lH9su","https://ap.wps.com/l/cbCairAM1G1lH9su","pdf",1673926,"English","# Materials and methods\n## Tissue microarrays (TMAs)\n## Immunohistochemistry (IHC)\n## Statistical analysis and outcome association","[{\"question\":\"What was the main purpose of measuring E-cadherin in lung cancer samples?\",\"answer\":\"To determine how common reduced E-cadherin expression is across lung cancer subtypes and whether it relates to disease progression, clinicopathological features, and patient survival.\"},{\"question\":\"How was E-cadherin expression assessed in this study?\",\"answer\":\"E-cadherin expression was analyzed by immunohistochemistry (IHC) on a tissue microarray (TMA) containing 857 lung cancer tissue samples.\"},{\"question\":\"In which lung cancer subtype was E-cadherin loss more frequent?\",\"answer\":\"Loss of E-cadherin expression was reported as slightly more frequent in adenocarcinomas than in squamous cell carcinomas.\"},{\"question\":\"What does reduced E-cadherin expression indicate about prognosis?\",\"answer\":\"Reduced E-cadherin expression was significantly associated with advanced pT stage and high grade in adenocarcinomas, and univariate outcome analysis linked it to poorer survival in NSCLCs and adenocarcinomas.\"}]","Low E-cadherin expression is associated with poor prognosis in pulmonal adenocarcinoma | PDF",1790100664,25,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/66350040975018a7bf7db8e15df94974.webp",983,1291,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df56659ef2e7792efed38d66f0e76694.webp",982,1290,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/647105f0b2ff53d2675d4fdb6d951611.webp",981,1289,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/76eae75a0748bf594d9e0c08553f12bf.webp",980,1287]